Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Stat Med. 2011 Dec 30;30(30):3507-19. doi: 10.1002/sim.4398. Epub 2011 Dec 5.
We propose an approach to analyze survival time in a crossover clinical trial by performing a primary ranking on whether events occur and a secondary ranking on event times. This hierarchical ranking method is meant to reflect the idea that the goal of therapy is to prevent a clinical event and, failing that, to delay the occurrence of the event, hopefully for a substantial amount of time. We compare our approach with other methods including one method proposed by Feingold and Gillespie, a recommended procedure. The power is similar in many settings, but the hierarchical ranking can have substantially greater power under certain censoring patterns and also under a cure model, or models where treatment induces a substantial delay in some fraction of patients. We additionally feel that the hierarchical ranking method should be more clinically relevant in many settings. The method can also be applied to continuous outcomes censored by a limit of detection, such as HIV viremia.
我们提出了一种在交叉临床试验中分析生存时间的方法,方法是对是否发生事件进行主要排序,并对事件时间进行次要排序。这种层次排序方法旨在反映这样一种理念,即治疗的目标是预防临床事件,而如果未能做到这一点,则希望延迟事件的发生,最好是在相当长的一段时间内。我们将我们的方法与其他方法进行了比较,包括 Feingold 和 Gillespie 提出的一种方法,这是一种推荐的方法。在许多情况下,功效相似,但在某些删失模式下,以及在治愈模型下,或者在治疗导致某些患者出现实质性延迟的情况下,层次排序方法的功效可以大大提高。我们还认为,在许多情况下,层次排序方法在临床方面应该更具相关性。该方法还可以应用于通过检测极限进行连续结果删失的情况,例如 HIV 病毒载量。